Compare Sana Biotechnology Inc (SANA) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Vanguard Total International Stock Index Fund ETF trades at $84.72. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VXUS | |
|---|---|---|
Market Cap | $873.84M | — |
Sector | Health | Sector/Thematic |
52-Week High | $5.92 | $87.06 |
52-Week Low | $2.68 | $68.24 |
Enterprise Value | $848.03M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
VXUS trades at $83.07, down 0.36% with a bearish technical signal from moving averages. The ETF provides diversified international exposure to over 8,700 non-U.S. stocks across developed and emerging markets. Recent institutional buying activity includes Greenwood Gearhart increasing its position by 45.8% in Q1 2026. Technical indicators show neutral oscillators but bearish momentum with support at $82 and resistance at $84.
The outlook remains cautious due to global economic uncertainty, though VXUS offers diversification benefits for U.S.-centric portfolios. Key risks include currency fluctuations and emerging market volatility. Analyst sentiment is mixed with some recommending international diversification while others caution about growth/inflation dynamics in global markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
